What is HC Wainwright’s Forecast for MIST FY2029 Earnings?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Stock analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Milestone Pharmaceuticals in a research report issued on Monday, January 27th. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $1.86 for the year. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share.

Milestone Pharmaceuticals Trading Up 1.0 %

Shares of MIST stock opened at $2.00 on Tuesday. The company has a 50 day moving average of $1.97 and a 200-day moving average of $1.67. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $2.75. The firm has a market cap of $106.66 million, a P/E ratio of -2.47 and a beta of 1.78.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Large investors have recently modified their holdings of the stock. Valeo Financial Advisors LLC increased its stake in shares of Milestone Pharmaceuticals by 100.0% during the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after purchasing an additional 10,000 shares during the last quarter. PVG Asset Management Corp purchased a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth approximately $46,000. Atria Investments Inc increased its stake in shares of Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after purchasing an additional 12,430 shares during the last quarter. Finally, BML Capital Management LLC increased its stake in shares of Milestone Pharmaceuticals by 3.0% during the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock worth $1,727,000 after purchasing an additional 33,196 shares during the last quarter. Hedge funds and other institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.